Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic ...
WEBSep 18, 2024 · GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 13% sales growth and strategic innovations in R&D, contrasted with ...
Press releases | GSK US
WEBUS FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk.
GSK Announces FDA Acceptance of New Meningococcal Jab BLA
WEBApr 17, 2024 · The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.
GSK makes a strong start to 2024 with improving outlook for ...
WEBMay 1, 2024 · Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%) Dividend declared of 15p for …
GSK News
WEBStay updated on the latest news from GSK, a global healthcare company with innovative medicines, vaccines and consumer products.
US FDA approves GSK’s AREXVY, the world’s first respiratory ...
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
GSK shares fall as US narrows age recommendation for RSV vaccines
WEBJun 27, 2024 · GSK shares fell more than 6 per cent on Thursday morning after US health officials recommended restricting the use of vaccines for respiratory syncytial virus, an area in which the British ...
GSK delivers strong 2023 performance and upgrades growth ...
WEBJan 31, 2024 · Broad-based performance drives sales, profits and earnings growth: Total 2023 sales £30.3 billion +5% and +14% ex COVID. Vaccines sales +25%, +24% ex COVID. Shingrix £3.4 billion +17%, Arexvy £1.2 billion.
GSK shares tumble after Delaware court ruling on Zantac
WEBJun 3, 2024 · GSK shares dropped almost 10 per cent on Monday after a ruling from a Delaware judge left the UK drugmaker exposed to US jury trials over its allegedly carcinogenic heartburn treatment Zantac.
Skip to content